BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 6814473)

  • 1. Effect of ICRF-187 on doxorubicin-induced myocardial effects in the mouse and guinea pig.
    Perkins WE; Schroeder RL; Carrano RA; Imondi AR
    Br J Cancer; 1982 Oct; 46(4):662-7. PubMed ID: 6814473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy.
    Alderton P; Gross J; Green MD
    Cancer Res; 1990 Aug; 50(16):5136-42. PubMed ID: 2116226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ICRF 159 on adriamycin-induced cardiomyopathy in rats.
    Decorti G; Bartoli Klugmann F; Mallardi F; Klugmann S; Benussi B; Grill V; Baldini L
    Cancer Lett; 1983 May; 19(1):77-83. PubMed ID: 6406045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats.
    Herman EH; el-Hage A; Ferrans VJ
    Toxicol Appl Pharmacol; 1988 Jan; 92(1):42-53. PubMed ID: 3124293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles.
    Herman EH; Ferrans VJ; Myers CE; Van Vleet JF
    Cancer Res; 1985 Jan; 45(1):276-81. PubMed ID: 3917371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of ICRF-159 or ICRF-186 on cytotoxicity of daunorubicin and doxorubicin.
    Supino R
    Tumori; 1984 Apr; 70(2):121-6. PubMed ID: 6730012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity.
    Herman EH; Ferrans VJ
    Cancer Chemother Pharmacol; 1993; 32(6):445-9. PubMed ID: 8258192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
    Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
    Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine, and inhibition by ICRF-187.
    Zhang J; Clark JR; Herman EH; Ferrans VJ
    J Mol Cell Cardiol; 1996 Sep; 28(9):1931-43. PubMed ID: 8899552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines.
    Herman EH; Zhang J; Hasinoff BB; Chadwick DP; Clark JR; Ferrans VJ
    Cancer Chemother Pharmacol; 1997; 40(5):400-8. PubMed ID: 9272116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats.
    Herman EH; Zhang J; Ferrans VJ
    Cancer Chemother Pharmacol; 1994; 35(2):93-100. PubMed ID: 7987999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myocardial effects of mitoxantrone and doxorubicin in the mouse and guinea pig.
    Perkins WE; Schroeder RL; Carrano RA; Imondi AR
    Cancer Treat Rep; 1984 Jun; 68(6):841-7. PubMed ID: 6733698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs.
    Herman EH; Ferrans VJ; Young RS; Hamlin RL
    Cancer Res; 1988 Dec; 48(23):6918-25. PubMed ID: 3141049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of cardiotoxic, nephrotoxic and neurotoxic effects of doxorubicin by ICRF-159.
    Tian Hu S; Brändle E; Zbinden G
    Pharmacology; 1983; 26(4):210-20. PubMed ID: 6844396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment with ICRF-187 allows a marked increase in the total cumulative dose of doxorubicin tolerated by beagle dogs.
    Herman EH; Ferrans VJ; Young RS; Hamlin RL
    Drugs Exp Clin Res; 1988; 14(9):563-70. PubMed ID: 3147886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ameliorative effects of ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the cardiotoxicity induced by doxorubicin or by isoproterenol in the mouse.
    Flandina C; Sanguedolce R; Rausa L; D'Alessandro N
    Res Commun Chem Pathol Pharmacol; 1990 Dec; 70(3):259-72. PubMed ID: 2128759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine.
    Herman EH; Ferrans VJ
    Lab Invest; 1983 Jul; 49(1):69-77. PubMed ID: 6408310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model.
    Alderton PM; Gross J; Green MD
    Cancer Res; 1992 Jan; 52(1):194-201. PubMed ID: 1727379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat.
    Yeung TK; Jaenke RS; Wilding D; Creighton AM; Hopewell JW
    Cancer Chemother Pharmacol; 1992; 30(1):58-64. PubMed ID: 1586981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of doxorubicin cytotoxicity by (+)-1,2-bis-(3,5-dioxopiperazinyl-1-yl) propane (ICRF-187) in human leukemic HL-60 cells.
    Monti E; Sinha BK
    Cancer Commun; 1990; 2(4):145-9. PubMed ID: 2164412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.